Welcome Veterinarians
Since 2007, thousands of dogs1 have been treated with an innovative therapeutic vaccine from Merial as an adjunct therapy for canine oral melanoma (COM). The vaccine was available under a conditional license for use following surgical removal of primary oral melanoma tumors.
Merial is pleased to announce that this targeted DNA vaccine – the first targeted DNA vaccine that aids in extending survival time in dogs treated for COM – has received full licensure from the USDA as ONCEPT® Canine Melanoma Vaccine, DNA.* ONCEPT is now available to specialists practicing veterinary oncology.
If you are interested in receiving the latest news and data concerning ONCEPT Canine Melanoma Vaccine, DNA, please contact Merial Technical Solutions at 1-888-MERIAL-1, Option 3.
1Grosenbaugh, et al. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. AJVR 2011;72: 1631-1638
*Product indications: Vaccine aids in extending survival times of dogs with stage II or stage III oral melanoma and for which local disease control has been achieved.
